Novel Therapies for Hepatitis C: Insights from the Structure of the Virus

New opportunities in anti-hepatitis C virus drug discovery: Targeting NS4B

(2011) Roopa Rai et al.   ANTIVIRAL RESEARCH

Sequence and Phenotypic Analysis for Resistance Monitoring in Hepatitis C Virus Drug Development: Recommendations From the HCV DRAG

(2011) Ann D. Kwong et al.   GASTROENTEROLOGY

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus Genotype 1 Infection, But With Issues Still Pending

(2011) Jean–Michel Pawlotsky   GASTROENTEROLOGY

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients

(2011) Frank Wagner et al.   HEPATOLOGY

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

(2011) Jean-Michel Pawlotsky   HEPATOLOGY

New direct-acting antivirals' combination for the treatment of chronic hepatitis C

(2011) Tarik Asselah et al.   LIVER INTERNATIONAL

Future hepatitis C virus treatment: interferon-sparing combinations

(2011) Edward Gane   LIVER INTERNATIONAL

A diverse range of gene products are effectors of the type I interferon antiviral response

(2011) John W. Schoggins et al.   NATURE

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435

(2010) O. Lenz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Synthesis and anti-HCV activity of 3′,4′-oxetane nucleosides

(2010) Wonsuk Chang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus

(2010) Christopher McGuigan et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction

(2010) Alexander J. Thompson et al.   GASTROENTEROLOGY

Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C

(2010) Patrick Marcellin et al.   GASTROENTEROLOGY

Outcome of sustained virological responders with histologically advanced chronic hepatitis C

(2010) Timothy R. Morgan et al.   HEPATOLOGY

Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models

(2010) Emmanuel Thomas et al.   HEPATOLOGY

Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977

(2010) Eisuke Murakami et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study

(2010) Nicole Forestier et al.   JOURNAL OF HEPATOLOGY

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

(2010) Michael P. Manns et al.   JOURNAL OF HEPATOLOGY

RG7128 Alone or in Combination with Pegylated Interferon‐α2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV‐Infected Patients

(2010) Sophie Le Pogam et al.   JOURNAL OF INFECTIOUS DISEASES

Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

(2010) John A. McCauley et al.   JOURNAL OF MEDICINAL CHEMISTRY

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

(2010) Paul Y Kwo et al.   LANCET

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

(2010) Edward J Gane et al.   LANCET

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C

(2010) Jacques Fellay et al.   NATURE

Telaprevir for Previously Treated Chronic HCV Infection

(2010) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A

(2010) Lotte Coelmont et al.   PLoS One

Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory

(2010) Jérôme Gouttenoire et al.   REVIEWS IN MEDICAL VIROLOGY

Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus

(2010) L. Rong et al.   Science Translational Medicine

Investigational drugs for hepatitis C

(2009) Robert Flisiak et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

(2009) Henk W. Reesink et al.   GASTROENTEROLOGY

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

(2009) Christoph Sarrazin et al.   GASTROENTEROLOGY

The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients

(2009) Robert Flisiak et al.   HEPATOLOGY

Evaluation of VCH-759 monotherapy in hepatitis C infection

(2009) Curtis Cooper et al.   JOURNAL OF HEPATOLOGY

Antiviral resistance and specifically targeted therapy for HCV (STAT-C)

(2009) A. J. V. Thompson et al.   JOURNAL OF VIRAL HEPATITIS

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

(2009) Vijayaprakash Suppiah et al.   NATURE GENETICS

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

(2009) Yasuhito Tanaka et al.   NATURE GENETICS

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection

(2009) R. E. Lanford et al.   SCIENCE

Fluvastatin Inhibits Hepatitis C Replication in Humans

(2008) Ted Bader et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Early steps of the hepatitis C virus life cycle

(2008) Jean Dubuisson et al.   CELLULAR MICROBIOLOGY

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus

(2008) Robert Flisiak et al.   HEPATOLOGY

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

(2008) Eric Lawitz et al.   JOURNAL OF HEPATOLOGY

The Hepatitis C Virus NS4B Protein Can trans-Complement Viral RNA Replication and Modulates Production of Infectious Virus

(2008) D. M. Jones et al.   JOURNAL OF VIROLOGY